PRIVILEGED AND CONFIDENTIAL ATTORNEY-CLIENT PRIVILEGE / ATTORNEY WORK PRODUCT
CALDERWOOD & HARKNESS LLP Tax Department 1735 Market Street, Suite 3100 Philadelphia, PA 19103
September 28, 2022
MEMORANDUM
FROM: Leila Nazari, Working Associate, Tax Department Calderwood & Harkness LLP
TO: Leonard Cross, Partner, Tax Department Sylvia Hartwell, Of Counsel, Tax Department Garrett Simmons, Lead Associate, Tax Department
RE: IRC § 367(d) and Outbound IP Transfer Considerations — Penterra Pharmaceuticals Corp. IRS Examination Defense (TY 2017–2020)
MATTER NO.: 1018-00009
CLIENT: Penterra Pharmaceuticals Corp. (EIN: 22-3741856)
THIS MEMORANDUM IS PROTECTED BY THE ATTORNEY-CLIENT PRIVILEGE AND THE WORK PRODUCT DOCTRINE. IT IS PREPARED IN ANTICIPATION OF LITIGATION AND FOR THE PURPOSE OF RENDERING LEGAL ADVICE TO PENTERRA PHARMACEUTICALS CORP. IN CONNECTION WITH IRS EXAMINATION LB&I-NE-TP-2022-00641. DO NOT DISTRIBUTE, COPY, OR DISCLOSE WITHOUT THE EXPRESS WRITTEN AUTHORIZATION OF LEONARD CROSS, RESPONSIBLE PARTNER. IF THIS MEMORANDUM IS INADVERTENTLY DISCLOSED, ALL PRIVILEGES ARE EXPRESSLY RESERVED AND NOT WAIVED.
I. Executive Summary
The purpose of this memorandum is to analyze the risk that the Internal Revenue Service may attempt to recharacterize elements of Penterra Pharmaceuticals Corp.'s ("PPC") cost-sharing arrangement ("CSA") with Penterra Biopharma International DAC ("PBI") as an outbound transfer of intangible property subject to IRC § 367(d), rather than — or in addition to — making adjustments under IRC § 482. This analysis is undertaken in the context of the IRS's ongoing examination of PPC's federal income tax returns for Tax Years 2017 through 2020 and is designed to inform our overall examination defense strategy.
The current IRS examination (Exam Team LB&I-NE-TP-2022-00641, opened May 16, 2022, under Supervisory Revenue Agent Gerald Meskill, with Lead Revenue Agent Patricia Dunleavy) covers TY 2017–2020 and has focused primarily on IRC § 482 transfer pricing adjustments. Specifically, the IRS has concentrated on challenging the CSA cost-sharing ratios and the royalty rates applied to PPC's legacy IP license arrangement with PBI. The examination has generated significant activity since its opening, with forty-seven (47) Information Document Requests ("IDRs") issued between June 2022 and September 2023.
By way of background, the CSA between PPC and PBI was executed effective July 1, 2012. Under the CSA, PBI acquired the right to develop and exploit PPC's pharmaceutical IP portfolio outside the Americas (defined as North America, Central America, South America, and the Caribbean) in exchange for a Platform Contribution Transaction ("PCT") payment of $312 million, which represented a lump-sum buy-in to PPC's pre-existing intangible property portfolio, consisting primarily of clinical-stage and approved oncology compounds.
The IRS examination team is supported by IRS Attorney-Advisor Franklin Rosario and Senior Counsel Donna Hirabayashi from the Office of Chief Counsel. The involvement of Chief Counsel personnel raises the possibility — though not the certainty — that § 367(d) theories could be raised as alternative or supplemental positions to the IRS's § 482 adjustments. This concern is heightened by the fact that Chief Counsel attorneys are more likely to identify and pursue statutory theories beyond the traditional § 482 transfer pricing framework.
Conclusion. Based on our analysis of the applicable statutory provisions, Treasury regulations, case law, IRS administrative practice, and the specific facts of PPC's CSA with PBI, we conclude that the risk of a successful § 367(d) recharacterization is LOW overall. The structure of the CSA as a qualified cost-sharing arrangement under Treasury Regulation § 1.482-7, coupled with the specific coordination rule set forth in Treasury Regulation § 1.482-7(j)(3), provides significant insulation against § 367(d) recharacterization. The IRS's more probable approach remains a § 482 adjustment to the CSA cost-sharing ratios and legacy IP royalty rates, and the examination posture to date is consistent with this assessment.
We recommend ongoing monitoring of IDR requests for any signals that the IRS is developing a § 367(d) theory, with particular attention to any requests for information regarding the formation or capitalization of PBI, capital contributions to Penterra Holdings Luxembourg S.à r.l. ("PHL") or PBI, or any § 351 analysis. We do not recommend affirmative § 367(d) defense preparation at this time beyond ensuring that the § 482 defense inherently and adequately addresses the underlying factual and legal issues that would arise in a § 367(d) context.
II. Factual Background
A. Corporate Structure
Penterra Pharmaceuticals Corp. ("PPC") is a Delaware corporation, publicly traded on the Nasdaq Stock Market under the ticker symbol "PPCA," and headquartered at 2200 Independence Boulevard, Princeton Junction, New Jersey 08550. PPC is a specialty pharmaceuticals and biotechnology company focused on oncology, immunology, and rare disease therapeutics. For fiscal year 2020, PPC reported revenue of $6.82 billion, pre-tax income of $1.47 billion, and employed approximately 14,500 individuals globally. PPC's senior management includes Chief Executive Officer Catherine Falk, Chief Financial Officer Rajesh Iyer, General Counsel Deborah Staines, and Vice President of Global Tax Marcus Whitfield.
Penterra Holdings Luxembourg S.à r.l. ("PHL") is an intermediate holding entity organized as a société à responsabilité limitée under Luxembourg law, with its registered address at 14, rue Aldringen, L-1118 Luxembourg (Luxembourg Registre de Commerce et des Sociétés Number B 168452). PHL is 100% owned by PPC and in turn holds 100% ownership of PBI. Critically for purposes of this analysis, PHL is treated as a disregarded entity for U.S. federal income tax purposes. As a consequence, for all purposes under Subchapter C and the international tax provisions of the Code, PPC is treated as the direct owner of PBI, and any transfer of property from PPC through PHL to PBI is treated as a direct transfer from PPC to PBI. The implications of PHL's disregarded entity status for the § 367(d) analysis are discussed in detail in Section VII below.
Penterra Biopharma International DAC ("PBI") is a designated activity company organized under Irish law, registered at 4th Floor, Claremont House, Sandyford Business Park, Dublin D18 K7T4, Ireland (Irish Tax Reference Number 3218764T). PBI was incorporated on March 15, 2012, approximately three and one-half months prior to the effective date of the CSA. PBI's Managing Director is Aidan Naughton. As of the end of 2020, PBI employed 185 individuals — a significant increase from the 52 employees at inception in 2012. PBI reported fiscal year 2020 revenue of €2.14 billion and pre-tax income of €1.06 billion. PBI maintains approximately 18,000 square feet of office space at its Dublin headquarters. PBI is subject to the Irish standard trading corporation tax rate of 12.5%, with the Knowledge Development box ("KDB") rate of 6.25% applicable to qualifying income from fiscal year 2016 forward. PBI's Irish tax advisors are Thornbury & Keogh, with Ciarán Thornbury serving as lead partner, at 22 Fitzwilliam Square, Dublin 2.
Penterra Manufacturing Ireland Ltd. ("PMI") is an Irish private limited company (Companies Registration Office Number 512347) located at Unit 7, Ringaskiddy Industrial Estate, Co. Cork T12 PX29, Ireland. PMI serves as a contract manufacturer for PBI under a cost-plus 8% intercompany manufacturing arrangement. PMI employs approximately 620 individuals in its manufacturing operations. While PMI is not directly involved in the § 367(d) analysis, its presence in Ireland supports the overall narrative that PPC's Irish operations have genuine substance and economic activity.
PBI maintains its primary banking relationship with Glenmore Bank Ireland plc.
B. The Cost-Sharing Arrangement and Platform Contribution Transaction
The CSA between PPC and PBI was executed with an effective date of July 1, 2012, and was structured to comply with the requirements for a qualified cost-sharing arrangement ("QCSA") under Treasury Regulation § 1.482-7. Under the terms of the CSA, PBI acquired the right to develop and exploit PPC's pharmaceutical intangible property portfolio — including patents, know-how, clinical data, regulatory filings, and related intangibles — for all territories outside the Americas. The Americas territory, defined to include North America, Central America, South America, and the Caribbean, was retained by PPC.
As part of the CSA, PBI made a Platform Contribution Transaction payment of $312 million as a lump sum to PPC on July 1, 2012. The PCT payment represented PBI's buy-in consideration for access to PPC's pre-existing intangible property, which at that time consisted primarily of clinical-stage and approved oncology compounds. The PCT payment was determined through an arm's-length valuation conducted at that time and is discussed in greater detail in Section V.B below in connection with the IRS's valuation challenge.
In addition to the PCT payment, PBI has made ongoing cost-sharing payments representing its proportionate share of qualified research and development expenditures, based on the parties' reasonably anticipated benefits from the intangible development activities. The cost-sharing percentages and corresponding payments for the examination years are as follows:
The increasing cost-share percentages across the examination period reflect PBI's growing share of reasonably anticipated benefits from the CSA intangible development activities, driven by the expansion of non-Americas markets and the maturation of the product portfolio in PBI's territory.
The key pharmaceutical products covered by the CSA include the following:
• Veritaxol (oncology): 2020 global net sales of $3.12 billion, of which non-Americas net sales were $1.34 billion.
• Imvara (immunology): 2020 global net sales of $1.87 billion, of which non-Americas net sales were $0.79 billion.
• Cerulon (rare disease): 2020 global net sales of $0.62 billion, of which non-Americas net sales were $0.28 billion.
C. The Legacy IP Royalty Arrangement
Separately from the CSA, PBI licensed certain legacy compounds from PPC — specifically, compounds of a pre-2012 vintage that were not covered by the CSA — under a conventional intercompany license agreement. The license granted PBI exploitation rights for the non-Americas territory at a royalty rate of 4.5% of net sales.
The relevant legacy product net sales and corresponding royalty payments for the examination years are as follows:
The declining trajectory of legacy product sales is consistent with the aging product lifecycle and the patent expiration schedule for these pre-2012 compounds. The IRS has proposed adjusting the royalty rate from 4.5% to 11.0%, which is discussed in the § 482 defense memorandum and is referenced here only insofar as it relates to the potential interplay with § 367(d).
D. PBI's Functions and Economic Substance
PBI maintains a robust operational presence in Dublin and performs genuine development, enhancement, maintenance, protection, and exploitation ("DEMPE") functions with respect to the CSA intangibles in its assigned territory. The economic substance of PBI's operations is directly relevant to the § 367(d) analysis because the IRS's ability to recharacterize the CSA as a sham or as lacking economic substance is a precondition to several of the § 367(d) theories discussed in Section V below.
Specifically, PBI employs personnel in the following functional areas: regulatory affairs, medical affairs, commercial strategy, and supply-chain management. These employees are based in Dublin and carry out their functions from PBI's 18,000 square-foot office facility. PBI bore market risk for all non-Americas territories and made key commercial decisions — including product pricing, market-entry timing and sequencing, distribution partner selection and management, and regulatory filing strategy — across sixty-eight (68) country markets during the examination period.
PBI's board of directors held forty-two (42) meetings in Dublin during the period from 2017 through 2020, consisting of quarterly scheduled meetings and special sessions convened as needed. Board meetings were conducted in person in Dublin and addressed strategic, commercial, regulatory, and financial matters within PBI's scope of operations.
PBI incurred cumulative regulatory expenditures and submission costs of €47.2 million during the 2017–2020 period, reflecting its active engagement with regulatory authorities across multiple jurisdictions in Europe, Asia-Pacific, the Middle East, and Africa.
PBI's functions, assets, and risks were comprehensively documented in the functional analysis prepared by Calderwood & Harkness in October 2022, which was provided to the examination team in response to IDR No. 12. That analysis demonstrates genuine DEMPE participation by PBI and supports the position that PBI is not merely a passive recipient of IP rights.
E. PHL's Disregarded Entity Status
As noted above, PHL is treated as a disregarded entity for U.S. federal income tax purposes. This characterization means that, for purposes of IRC § 367(d) — as well as IRC § 482 and the Subpart F and GILTI provisions — PPC's ownership of PBI through PHL is treated as if PPC directly owned PBI. Any transfer of property from PPC to PBI that was routed through PHL is treated as a direct transfer from PPC (a U.S. person) to PBI (a foreign corporation).
This treatment is critical for the § 367(d) analysis. Under § 367(d)(1), the statute applies to transfers of intangible property by a "United States person" to a "foreign corporation." Because PHL is disregarded, PPC is the relevant U.S. person, and PBI is the relevant foreign corporation. There is no separate § 367(d) event at the PPC-to-PHL level (as PHL is not a separate entity for federal tax purposes) and no separate event at the PHL-to-PBI level independent of the PPC-to-PBI transfer. This simplification is discussed further in Section VII.
F. The IRS Examination
The IRS opened its examination of PPC's federal income tax returns for Tax Years 2017 through 2020 on May 16, 2022, by issuance of Letter 2205-A. The examination is being conducted under the LB&I division, Northeast region, Transfer Pricing practice area, under Exam Team designation LB&I-NE-TP-2022-00641. Supervisory Revenue Agent Gerald Meskill oversees the examination, with Lead Revenue Agent Patricia Dunleavy conducting the day-to-day examination activities. IRS economist Dr. Alan Washburne has been engaged to support the transfer pricing analysis.
Significantly, IRS Attorney-Advisor Franklin Rosario and Senior Counsel Donna Hirabayashi from the Office of Chief Counsel have been assigned to advise the examination team. The involvement of two Chief Counsel attorneys — including a Senior Counsel — is notable and suggests that the IRS views this examination as involving complex legal issues that may extend beyond routine § 482 transfer pricing adjustments.
The IRS's primary positions to date, as reflected in the IDR requests and informal communications with the examination team, appear focused on three principal areas under IRC § 482:
1. CSA Cost-Sharing Ratio Adjustments. The IRS is proposing to increase PBI's cost-sharing percentages by approximately 8 to 12 percentage points across the examination years, arguing that PBI's reasonably anticipated benefits were higher than the ratios employed by PPC.
2. Legacy IP Royalty Rate Adjustment. The IRS is proposing to increase the legacy IP royalty rate from 4.5% to 11.0% of net sales, based on comparable uncontrolled transaction analysis and the IRS's view that PPC's pre-existing IP was significantly more valuable than reflected in the existing royalty rate.
3. Economic Substance of PBI. The IRS has questioned whether PBI possesses sufficient DEMPE functions and whether key decision-making and intangible development functions remained in the United States, which would support either a reallocation of income under § 482 or, potentially, a recharacterization of the arrangement.
No formal Notice of Proposed Adjustment ("NOPA") asserting a § 367(d) position has been issued as of the date of this memorandum. The IRS has not, to our knowledge, requested information specifically related to § 367(d) analysis, § 351 transactions, or the capitalization of PBI. However, the involvement of Chief Counsel attorneys and the active economic substance inquiry warrant continued vigilance on this front.
As of the date of this memorandum, the IRS's proposed § 482 adjustments, if fully sustained, would total approximately $380.4 million in net proposed adjustments across TY 2017–2020. The IRS has already permitted a correlative offset of $42.65 million relating to the overlap between the CSA cost-sharing adjustment and the legacy royalty rate adjustment.
III. Legal Framework — IRC § 367(d)
A. Statutory Text and Purpose
IRC § 367(d) was enacted to address the concern that U.S. taxpayers could transfer valuable intangible property to controlled foreign corporations in tax-free exchanges — thereby shifting future income derived from those intangibles to low-tax jurisdictions — without adequate recognition of gain or ongoing compensation to the U.S. transferor. The provision operates by overriding the nonrecognition rules that would otherwise apply to such transfers and instead imputing a deemed royalty stream to the U.S. transferor.
Specifically, IRC § 367(d)(1) provides that if a United States person transfers intangible property (as defined in § 367(d)(4), which references the definition in § 936(h)(3)(B)) to a foreign corporation in an exchange described in §§ 332, 351, 354, 355, 356, or 361, the transferor shall be treated as having sold the intangible property in exchange for annual payments contingent on the productivity, use, or disposition of such property. In other words, the statute creates a deemed royalty stream running from the foreign transferee to the U.S. transferor over the useful life of the intangible property, regardless of whether any actual royalty is paid.
The fundamental purpose of § 367(d) is to prevent "outbound" transfers of valuable U.S.-developed intellectual property to foreign affiliates at undervalued or zero consideration, thereby ensuring that the United States retains taxing jurisdiction over income properly attributable to intangible property developed through U.S. research and development efforts. The provision serves as a backstop to the general transfer pricing rules under § 482 by specifically targeting nonrecognition transactions that, absent § 367(d), would permit a U.S. person to contribute intangible property to a foreign corporation tax-free and subsequently benefit from the foreign corporation's exploitation of that property in a low-tax jurisdiction.
IRC § 367(d)(2) provides that the amounts treated as received by the transferor under § 367(d)(1) are to be "commensurate with the income attributable to such intangible." This "commensurate with income" standard was added by the Tax Reform Act of 1986, Pub. L. No. 99-514, § 1231(e), and reflects Congress's view that the compensation for intangible property transfers — whether in the form of actual or deemed payments — must bear a reasonable relationship to the actual economic returns generated by the intangible. The "commensurate with income" standard permits the deemed royalty to be recalculated annually based on actual results, thereby preventing taxpayers from undervaluing intangibles at the time of transfer and locking in artificially low deemed royalty rates.
IRC § 367(d)(4) defines "intangible property" by cross-reference to IRC § 936(h)(3)(B), which includes: patents, inventions, formulae, processes, designs, patterns, and know-how; copyrights and literary, musical, or artistic compositions; trademarks, trade names, and brand names; franchises, licenses, and contracts; methods, programs, systems, procedures, campaigns, surveys, studies, forecasts, estimates, customer lists, and technical data; and any similar item that has substantial value independent of the services of any individual. This is a broad definition that encompasses virtually all forms of intangible property that might be transferred in a pharmaceutical company context, including the patents, clinical data, regulatory filings, know-how, formulas, and trade secrets that comprise PPC's pharmaceutical IP portfolio.
B. Scope of "Transfer" Under § 367(d)
A critical threshold issue under § 367(d) is whether a "transfer" within the meaning of the statute has occurred. Section 367(d)(1) applies only to transfers of intangible property in exchanges described in one of the specified nonrecognition provisions: IRC §§ 332 (complete liquidations of subsidiaries), 351 (transfers to controlled corporations), 354, 355, and 356 (corporate reorganizations and distributions), and 361 (nonrecognition in reorganizations).
This enumeration is significant because it limits § 367(d) to transactions that would otherwise qualify for nonrecognition treatment under the applicable corporate restructuring and formation provisions. An arm's-length sale of intangible property, a license of intangible property, or a cost-sharing arrangement that is structured as an ongoing contractual relationship — rather than as a capital contribution or corporate restructuring — does not constitute a "transfer" in an exchange described in the enumerated sections and therefore falls outside the scope of § 367(d).
The distinction between a § 367(d) transfer and an arm's-length transaction governed by § 482 is the central analytical framework for this memorandum. A cost-sharing arrangement structured under Treasury Regulation § 1.482-7 is treated under the regulatory framework as a separate contractual arrangement between controlled parties — not as a contribution of property to a controlled foreign corporation under § 351 or any other nonrecognition provision. As discussed in Section IV below, this structural characterization provides the primary basis for concluding that PPC's CSA with PBI is not subject to § 367(d).
C. The "Commensurate with Income" Standard
Both IRC § 367(d)(2) and IRC § 482 incorporate a "commensurate with income" requirement for intangible property transfers to controlled foreign entities. The legislative history of the Tax Reform Act of 1986 indicates that Congress intended these two provisions to work in tandem but to address fundamentally different categories of transactions: § 367(d) was designed to address nonrecognition transfers (i.e., contributions and exchanges) of intangible property, while § 482 was designed to address ongoing intercompany transactions, including licenses, services arrangements, and cost-sharing arrangements.
Under § 367(d), the deemed royalty is recalculated annually to reflect the actual income attributable to the transferred intangible property. This annual recalculation mechanism is designed to ensure that the U.S. transferor is adequately compensated over the entire useful life of the intangible, even if the value of the intangible increases significantly after the initial transfer.
Under § 482, the arm's-length standard requires that intercompany prices — including royalty rates, cost-sharing payments, and PCT payments — be tested against the prices that would prevail in comparable transactions between unrelated parties. The "commensurate with income" standard under § 482, as implemented through Treasury Regulation § 1.482-4(f)(2), permits periodic adjustments to the pricing of intangible property if actual results differ materially from the projections used to establish the original pricing.
While the economic analysis under both provisions is similar in nature — both ultimately seek to ensure that the U.S. entity receives appropriate compensation for the value of the intangible property — the legal mechanisms and computational methodologies differ in important respects. Under § 367(d), the compensation takes the form of a deemed royalty imputed to the U.S. transferor regardless of actual payments. Under § 482, the compensation takes the form of adjustments to actual intercompany prices to bring them into conformity with the arm's-length standard.
For PPC, the § 482 analysis already addresses the "commensurate with income" question through the CSA cost-sharing ratios, the PCT valuation, and the legacy IP royalty rates. The IRS's proposed adjustments under § 482 represent the IRS's view of what arm's-length pricing would require — and these adjustments, if sustained, would effectively capture the additional compensation that the IRS believes PPC should receive. A separate § 367(d) overlay would, in most circumstances, result in duplicative taxation of the same underlying economic returns.
D. Regulatory Framework — Treas. Reg. § 1.367(d)-1T
The Treasury Department promulgated temporary regulations under § 367(d) — Treasury Regulation § 1.367(d)-1T — which provide the mechanical rules for implementing the deemed annual royalty payments required by § 367(d)(1). Although these regulations remain in temporary form, they have been in effect since 1986 and continue to govern the application of § 367(d) pending the issuance of final regulations.
The temporary regulations address several key aspects of § 367(d) implementation. First, they establish the methodology for calculating the deemed annual royalty, which is determined on an annual basis to be commensurate with the income attributable to the transferred intangible property. Second, they address the useful life of the intangible property for purposes of determining the duration of the deemed royalty stream. In general, the deemed royalty continues for the entire useful life of the intangible, which may extend for twenty years or more in the case of pharmaceutical intellectual property with long product lifecycles. Third, the regulations provide certain election provisions and exceptions that may limit or modify the application of § 367(d) in specific circumstances. Fourth, and most relevant to this memorandum, the temporary regulations address the interaction between § 367(d) and § 482 — a topic discussed in greater detail in Section VI below.
The continued temporary status of the § 367(d) regulations introduces a degree of uncertainty regarding the precise mechanics of any § 367(d) adjustment, particularly in the context of complex intangible property transfers such as CSAs. This regulatory uncertainty is one factor that may discourage the IRS from pursuing § 367(d) theories in cases where a more fully developed § 482 regulatory framework is available.
IV. The CSA/PCT as Distinguished from a § 367(d) Transfer
A. Structural Analysis: CSA vs. Outbound IP Transfer
The fundamental structural distinction between PPC's CSA with PBI and an outbound transfer of intangible property subject to § 367(d) is that the CSA is a contractual cost-sharing arrangement governed by Treasury Regulation § 1.482-7, not a contribution of property to a controlled foreign corporation under § 351 or any other nonrecognition provision enumerated in § 367(d)(1).
Under the CSA, PBI acquired the right to develop and exploit pharmaceutical IP outside the Americas. PBI did not receive ownership of the underlying intangible property itself. PPC retained full ownership of all U.S. and Americas rights to the intangible property, and PBI's rights are contractual in nature — they arise from and exist within the framework of the CSA, not from a transfer of the intangible property itself. This distinction is not merely formalistic; it reflects the economic substance of the arrangement. PPC continues to bear the costs and risks of developing and exploiting the intangible property in the Americas, and PBI bears the costs and risks of development and exploitation in its assigned territory. Both parties share in the ongoing costs of intangible development in proportion to their reasonably anticipated benefits.
The PCT payment of $312 million compensated PPC for PBI's buy-in to the pre-existing intangible property portfolio as of the CSA's effective date. This payment is economically and legally distinct from a capital contribution of intangible property in exchange for stock or other equity interests. PBI did not issue any stock, equity interests, or other ownership rights to PPC in connection with the PCT payment. Rather, the PCT payment was an arm's-length cash payment from PBI to PPC for the value of the pre-existing intangible property rights that PBI was acquiring under the CSA. The transaction is akin to a purchase of territorial exploitation rights, not a capital contribution.
The ongoing cost-sharing payments — ranging from $186.15 million in 2017 to $255.52 million in 2020 — represent PBI's proportionate share of qualified R&D expenditures incurred under the CSA. These payments are made in accordance with the cost-sharing methodology prescribed by Treasury Regulation § 1.482-7 and reflect PBI's participation as a co-developer of intangible property, not a passive recipient of transferred IP. Each party's cost-sharing obligation is determined by its share of reasonably anticipated benefits from the CSA activities, and the payments are made on an ongoing, annual basis. These ongoing payments are the antithesis of a one-time transfer of property subject to § 367(d); they represent the ongoing economic participation of both parties in the development of shared intangible property.
B. Treas. Reg. § 1.482-7(j)(3): Coordination Rule
The most significant regulatory protection against § 367(d) recharacterization is the coordination rule set forth in Treasury Regulation § 1.482-7(j)(3). This regulation specifically addresses the intersection between the § 482 cost-sharing arrangement rules and § 367(d).
Under Treasury Regulation § 1.482-7(j)(3), a PCT payment made in connection with a qualified cost-sharing arrangement is generally treated as an arm's-length payment governed by § 482, not as a transfer of intangible property subject to § 367(d). The regulation reflects the Treasury Department's recognition that the § 482 cost-sharing framework provides a comprehensive regime for testing and adjusting the pricing of intangible property rights shared between controlled parties under a CSA, and that the imposition of § 367(d) deemed royalties on top of the § 482 framework would create duplicative and potentially conflicting obligations.
The IRS itself has acknowledged, in both the regulatory text and the preambles accompanying the cost-sharing arrangement regulations, that a properly structured CSA with an arm's-length PCT payment is not a § 367(d) transfer. This acknowledgment is significant because it represents the considered position of the Treasury Department and the IRS — the very agency now examining PPC — that the § 482/CSA framework is the exclusive mechanism for addressing transfer pricing disputes arising from cost-sharing arrangements.
The coordination rule under Treasury Regulation § 1.482-7(j)(3) is the primary bulwark against § 367(d) recharacterization in this case. So long as PPC's CSA with PBI is recognized as a qualified cost-sharing arrangement under § 1.482-7 — and the IRS has not, to date, taken the position that the CSA fails to qualify as a QCSA — the PCT payment and ongoing cost-sharing payments are subject to § 482 and the arm's-length standard, not to § 367(d) and the deemed royalty regime.
C. The Legacy IP License — Separate from § 367(d) Concern
The legacy IP license, under which PBI pays a 4.5% royalty on net sales of pre-2012 compounds in the non-Americas territory, is a conventional intercompany license agreement. It does not involve a transfer of property in a nonrecognition transaction; rather, it is a straightforward arm's-length license of intangible property rights. As such, the legacy IP license is governed exclusively by IRC § 482 and Treasury Regulation § 1.482-4 (the regulations governing the pricing of intangible property licenses between controlled parties).
No § 367(d) issue arises from the legacy license arrangement. The IRS's proposed adjustment to the royalty rate (from 4.5% to 11.0%) is a pure § 482 dispute regarding the arm's-length royalty rate, and the legal and economic analysis applicable to that dispute is entirely distinct from any § 367(d) consideration. We note this conclusion here to clarify the scope of the § 367(d) analysis and to confirm that the legacy license does not introduce any additional § 367(d) exposure.
V. Risk Assessment: Potential § 367(d) Recharacterization Theories
We have identified four potential theories under which the IRS could attempt to apply § 367(d) to PPC's CSA with PBI. For each theory, we describe the analytical basis, assess the likelihood and potential impact, and evaluate the available defenses.
A. Theory 1: Recharacterization of the CSA as a Sham or Lacking Economic Substance
The most significant potential pathway to a § 367(d) adjustment would arise if the IRS were to successfully argue that the CSA lacks economic substance — a position that the IRS is already actively pursuing as part of its § 482 examination. The IRS's current economic substance challenge asserts that PBI lacks sufficient DEMPE functions and that key intangible development, enhancement, maintenance, protection, and exploitation functions remained in the United States with PPC personnel.
If the IRS were to prevail on this economic substance argument, a potential next step could be to recharacterize the arrangement as a de facto outbound transfer of intangible property from PPC to PBI. Under this theory, if PBI is not a genuine co-developer with real decision-making authority and operational capability, but merely a passive recipient of IP rights, then the CSA could be "collapsed" or recharacterized as a § 351 contribution of intangible property by PPC to PBI in exchange for PBI's equity or economic interest. Once recharacterized as a § 351 transfer, § 367(d) would apply to impose a deemed royalty stream on PPC.
Risk Assessment: LOW to MODERATE. We assess the risk of this theory succeeding as low to moderate. The "low" element of this assessment reflects the substantial evidence of PBI's economic substance and genuine DEMPE participation. PBI's 185 employees (as of 2020), 42 board meetings held in Dublin during the examination period, €47.2 million in cumulative regulatory expenditures and submissions, 68 country markets with independent commercial decision-making, and separate banking and treasury functions all provide strong evidence that PBI is a genuine operating entity with real functions, assets, and risks — not a shell entity passively receiving IP rights.
Our functional analysis, prepared in October 2022, comprehensively documents PBI's DEMPE functions across each of the key product lines. The analysis demonstrates that PBI exercises genuine decision-making authority over pricing, market entry, distribution partner selection, regulatory strategy, and commercial operations in its assigned territory.
The "moderate" element of this assessment reflects the fact that the IRS's economic substance challenge is active and being pursued with vigor. The examination team has devoted significant attention to the question of whether key functions remained in the United States, and the IRS may argue that PBI's personnel are primarily engaged in execution rather than strategic decision-making. If the IRS were to succeed in establishing that PBI lacks economic substance — a result we believe is unlikely but not impossible — the door to § 367(d) recharacterization would be opened.
We note, however, that even if the IRS were to succeed on the economic substance argument, the pathway from "CSA lacks economic substance" to "§ 367(d) deemed royalty" involves several additional analytical steps that the IRS would need to navigate, including demonstrating that the appropriate remedy is a § 367(d) deemed royalty rather than a § 482 allocation of income. The coordination rule and the general principle that § 482 is the preferred mechanism for CSA disputes would continue to provide a basis for resisting § 367(d) application even in a scenario where economic substance is partially undermined.
B. Theory 2: PCT Payment Undervaluation as Evidence of Disguised Transfer
The second potential theory rests on the significant gap between PPC's PCT valuation and the IRS's proposed valuation. The IRS's economist, Dr. Alan Washburne, has valued the pre-existing intangible property at $852 million, compared to PPC's PCT payment of $312 million. The resulting gap of $540 million could, in theory, support an argument that PBI received intangible property worth far more than it paid, suggesting that the unpaid portion constitutes a de facto capital contribution or transfer of intangible property that should be subject to § 367(d).
Under this theory, the IRS would argue that the $312 million PCT payment represents arm's-length compensation for only a portion of the intangible property rights transferred to PBI, and that the remaining $540 million in value was effectively contributed by PPC to PBI without adequate consideration — i.e., a disguised capital contribution subject to § 351 and, consequently, § 367(d).
Our Position on Valuation. PPC's independent valuation firm, Whitmore Valuation Group, led by Dr. Helena Vasquez and Dr. Rohan Chakrabarti, has determined the arm's-length range for the PCT payment to be $278 million to $361 million, using a discounted cash flow methodology with a weighted average cost of capital of 9.8%. PPC's actual PCT payment of $312 million falls comfortably within this arm's-length range. The IRS's higher valuation of $852 million is based, in part, on the IRS economist's use of a lower discount rate of 7.2%, which increases the present value of projected future cash flows. We believe the IRS's discount rate is insufficiently risk-adjusted for the development-stage pharmaceutical compounds that comprised a substantial portion of the pre-existing IP portfolio and does not adequately account for the inherent uncertainty in clinical-stage drug development.
Risk Assessment: LOW. Even assuming, arguendo, that the IRS were to prevail on a higher PCT valuation, the appropriate remedy would be a § 482 adjustment increasing the PCT payment or cost-sharing allocations — not a § 367(d) deemed royalty. The coordination rule under Treasury Regulation § 1.482-7(j)(3) specifically directs the resolution of PCT valuation disputes through the § 482 framework. The existence of a valuation disagreement does not, by itself, transform a cost-sharing arrangement into a nonrecognition transfer.
Moreover, the IRS's own regulatory framework contemplates that PCT valuations may be disputed and adjusted under § 482. Treasury Regulation § 1.482-7(g) provides detailed rules for determining the arm's-length PCT payment, including the use of various specified methods (income method, acquisition price method, market capitalization method, and residual profit split method). These methods are § 482 mechanisms; they do not invoke or depend upon § 367(d). The IRS's assertion that the PCT payment is too low is, at its core, a § 482 pricing dispute — not evidence of a § 367(d) transfer.
C. Theory 3: Post-Formation IP Migration
The third potential theory addresses the possibility that the IRS could argue that intangible property was effectively transferred from PPC to PBI outside the CSA framework. Under this theory, the IRS would contend that valuable know-how, trade secrets, or other intangible property migrated from PPC's U.S. operations to PBI through channels not contemplated or adequately compensated by the CSA — for example, through the migration of key employees, the informal sharing of proprietary knowledge, or the transfer of technical capabilities that were not captured in the CSA cost-sharing methodology.
If the IRS could establish that such a migration of intangible property occurred outside the CSA framework and without adequate arm's-length compensation, it could potentially argue that the migration constituted a transfer of intangible property subject to § 367(d). This theory would require the IRS to identify specific intangible property that was transferred, establish that the transfer occurred in a nonrecognition exchange (or, alternatively, argue for a recharacterization of the arrangement), and demonstrate that the transferred property was not adequately compensated under the CSA or otherwise.
Our Assessment. PPC's intangible property remains legally owned by PPC for the Americas territory and is exploited by PBI only under the contractual rights granted by the CSA. No outright IP ownership transfers occurred post-formation beyond the CSA framework. PPC did not contribute any intangible property to PBI outside of the CSA, and PBI's IP rights are limited to those granted under the CSA.
We acknowledge that PBI's employee base grew significantly — from 52 employees at inception in 2012 to 185 employees by the end of 2020 — and that this growth could theoretically be characterized by the IRS as a migration of know-how from PPC's U.S. operations to PBI's Dublin operations. However, we believe this argument would be a stretch. PBI's hiring has been primarily local — recruiting regulatory, medical affairs, commercial, and supply-chain professionals within Ireland and the broader European market. PBI's employees have developed their own expertise and capabilities in their assigned functions, and PBI has not been staffed primarily by transferees from PPC's U.S. operations. The growth in PBI's headcount is consistent with the growth of its commercial operations across 68 country markets and does not, in our view, constitute a "migration" of U.S.-developed intangible property.
Risk Assessment: LOW. This theory requires the IRS to establish both the existence of a specific intangible property transfer and the applicability of § 367(d) to that transfer. On the facts available, neither element is likely to be established. We recommend, however, that PPC continue to maintain clear records of employee hiring, training, and know-how development at PBI to rebut any future argument along these lines.
D. Theory 4: Recharacterization Under § 367(d) as Alternative to § 482 Adjustment
The fourth potential theory is procedural rather than substantive. The IRS could assert § 367(d) as an alternative position in a Notice of Proposed Adjustment or in litigation — that is, if the IRS is unable to sustain its § 482 adjustments, it could fall back on § 367(d) as an alternative ground for the same or similar proposed tax liability.
In practice, the IRS rarely pursues § 367(d) as a primary theory when a § 482 CSA adjustment is available. The § 482 regulatory framework for cost-sharing arrangements is significantly more developed than the § 367(d) temporary regulations, and § 482 provides the IRS with more flexible remedies — including adjustments to cost-sharing ratios, PCT payments, royalty rates, and income allocations — than the deemed royalty mechanism of § 367(d). The IRS's examination teams in the Transfer Pricing Practice area (where Dr. Alan Washburne operates) are trained and experienced in § 482 economics, not § 367(d) deemed-royalty calculations.
Moreover, IRS Chief Counsel attorneys Franklin Rosario and Donna Hirabayashi would need to support and develop any § 367(d) theory, as the statutory and regulatory analysis involved is more complex and less settled than the § 482 framework. To date, indications from the examination suggest that the IRS is focused on § 482 adjustments and has not signaled an intent to pursue a § 367(d) alternative theory.
Risk Assessment: LOW. While the IRS has the procedural ability to assert § 367(d) as an alternative position, the practical likelihood of this occurring is low given the IRS's examination posture, the relative maturity of the § 482 framework, and the coordination rule under Treasury Regulation § 1.482-7(j)(3).
VI. Interplay Between § 367(d) and § 482
A. Overlap and Potential Double Taxation
Both IRC § 367(d) and IRC § 482 address the pricing and taxation of intangible property transfers between controlled U.S. and foreign entities. This overlap creates a potential for double taxation if both provisions were applied to the same intangible property and the same transaction.
The coordination rule under Treasury Regulation § 1.482-7(j)(3) was designed specifically to prevent such duplicative application. The regulation provides that PCT payments under a qualified cost-sharing arrangement are governed by the § 482 framework, not by § 367(d). This coordination rule reflects the Treasury Department's recognition that applying both provisions to the same IP rights would result in the U.S. transferor being taxed twice on the same underlying economic returns — once through § 482 adjustments to cost-sharing payments and royalty rates, and again through § 367(d) deemed royalties.
If the IRS were to successfully apply § 482 to increase PPC's cost-sharing payments, PCT payment, or legacy royalty rates — with the current proposed adjustments totaling approximately $380.4 million in net proposed adjustments — a separate § 367(d) adjustment on the same intangible property would create a clear double-counting problem. PPC would be taxed on the § 482-adjusted income from the CSA and on the § 367(d) deemed royalty, both of which are intended to compensate PPC for the same intangible property.
The correlative offset principles under Treasury Regulation § 1.482-1(g) are also relevant to prevent double-counting. Under these principles, the IRS must ensure that an adjustment under § 482 that increases one party's income results in a corresponding decrease in the other party's income. The IRS has already applied these principles in the current examination, allowing a correlative offset of $42.65 million on the overlap between the CSA cost-sharing adjustment and the legacy royalty rate adjustment. Any attempt to layer a § 367(d) deemed royalty on top of the § 482 adjustments would raise similar double-counting concerns.
B. Exclusive Remedy Doctrine
Several courts and the IRS itself have addressed the question of whether § 482 and § 367(d) can be applied simultaneously to the same intangible property transfer. While there is no single case squarely holding that § 482 is the "exclusive remedy" in all CSA contexts, the weight of authority and the regulatory structure support the general principle that, where a CSA is structured as a qualified cost-sharing arrangement under Treasury Regulation § 1.482-7, the § 482 framework is the exclusive mechanism for testing and adjusting intercompany pricing of intangible property rights shared under the CSA.
The basis for this principle is both statutory and regulatory. Statutorily, § 367(d) applies only to "transfers" of intangible property in exchanges described in the enumerated nonrecognition provisions. A CSA that is recognized as a valid cost-sharing arrangement — rather than recharacterized as a disguised transfer — does not involve such an exchange. Regulatorily, Treasury Regulation § 1.482-7(j)(3) explicitly coordinates the two provisions by directing that PCT payments under a QCSA are governed by § 482.
The critical exception to this principle arises where the CSA is disregarded entirely — for example, for lack of economic substance or because it is treated as a sham transaction. In that scenario, the § 482 framework would no longer apply to govern the pricing of the arrangement, and § 367(d) could theoretically apply to the underlying deemed transfer of intangible property. This exception underscores the importance of the economic substance defense discussed in Section V.A above: so long as PBI's CSA participation is genuine and the CSA is recognized as a valid QCSA, the exclusive remedy principle operates to preclude § 367(d) application.
C. The "Commensurate with Income" Overlap
As noted in Section III.C above, both § 367(d)(2) and § 482 require that compensation for intangible property be "commensurate with income" from the intangible. This overlap means that the economic analysis required under both provisions is fundamentally similar — both seek to ensure that the U.S. entity is adequately compensated for the value of the intangible property in light of the actual income generated by that property.
Under § 482, as implemented through Treasury Regulation § 1.482-4(f)(2), the IRS may make periodic adjustments to the pricing of intangible property transfers if the actual results of the transaction differ materially from the projections used to establish the original pricing. This "periodic adjustment" mechanism is the § 482 equivalent of § 367(d)'s annual deemed royalty recalculation.
Under § 367(d)(2), the deemed royalty is recalculated annually based on the actual income attributable to the transferred intangible property. The annual recalculation is automatic; it does not require a showing of material deviation from projections.
In practice, the economic analyses required under both provisions converge on the same fundamental question: what is the arm's-length value of the intangible property, and what compensation is appropriate in light of the actual income generated? The legal mechanism differs — § 482 operates through price adjustments, while § 367(d) operates through deemed royalties — but the underlying economic inquiry is substantially the same.
For PPC, the § 482 analysis already addresses the "commensurate with income" question through the CSA cost-sharing ratios and the legacy IP royalty rates. The IRS's proposed § 482 adjustments represent the IRS's view of the arm's-length compensation that PPC should receive for the intangible property shared under the CSA and licensed under the legacy arrangement. A separate § 367(d) analysis would essentially duplicate this inquiry, with the additional procedural complexity of the deemed royalty mechanism.
VII. Impact of PHL's Disregarded Entity Status
PHL, the Luxembourg intermediate holding company through which PPC holds its 100% ownership interest in PBI, is treated as a disregarded entity for U.S. federal income tax purposes. The practical implications of this treatment for the § 367(d) analysis are straightforward but worth stating clearly.
Because PHL is disregarded, PPC is treated as the direct owner of PBI. Any transfer of intangible property from PPC to PBI that was effected through PHL — i.e., any transfer from PPC to PHL and then from PHL to PBI — is treated as a single, direct transfer from PPC (a United States person) to PBI (a foreign corporation). There is no separate § 367(d) event at the PPC-to-PHL step, because PHL is not a separate entity for federal tax purposes; and there is no separate § 367(d) event at the PHL-to-PBI step that is independent of the PPC-to-PBI transfer.
This simplifies the § 367(d) analysis in several respects. First, it eliminates the potential for the IRS to argue that a separate transfer of intangible property occurred at the PHL level — for example, that PPC contributed IP to PHL under § 351 (a Luxembourg-level event) and that this contribution itself triggers § 367(d). Because PHL is disregarded, there is no "contribution to PHL" for federal tax purposes; the only relevant transfer, if any, is the direct PPC-to-PBI transfer.
Second, the disregarded entity treatment means that the IRS cannot assert that a separate, independent § 367(d) analysis is required at the PHL level. The entire ownership chain is collapsed for federal tax purposes, and the § 367(d) analysis (to the extent it is relevant at all) is conducted at the PPC-to-PBI level.
Third, and conversely, the disregarded entity treatment ensures that any transfer of intangible property from PPC to PBI is treated as a direct transfer from a U.S. person to a foreign corporation — which is the type of transfer that § 367(d) is designed to address. There is no intermediate "domestic" step that would take the transfer outside of § 367(d)'s scope. This point, while not favorable to PPC in isolation, does not change the overall analysis: the question remains whether the CSA constitutes a "transfer" within the meaning of § 367(d), not whether the ownership structure interposes any barrier to § 367(d) application.
In summary, PHL's disregarded entity status simplifies the § 367(d) analysis without materially changing its outcome. The analysis depends on whether the CSA itself constitutes a § 367(d) transfer — a question answered in the negative for the reasons discussed in Sections IV and V above.
VIII. TCJA Considerations
The Tax Cuts and Jobs Act ("TCJA"), enacted December 22, 2017, and generally effective January 1, 2018, introduced several provisions that bear on the § 367(d) analysis for the portion of the examination period covering TY 2018, 2019, and 2020.
Corporate Tax Rate Reduction. The TCJA reduced the corporate income tax rate from 35% to 21%, effective for tax years beginning after December 31, 2017. This rate reduction affects the magnitude of any § 367(d) adjustment: a deemed royalty included in PPC's gross income would be taxed at 21% rather than 35% for TY 2018–2020. While the lower rate reduces the absolute dollar impact of a § 367(d) adjustment, it does not change the legal analysis of whether § 367(d) applies.
GILTI (IRC § 951A). The TCJA enacted the Global Intangible Low-Taxed Income provision under IRC § 951A, which requires U.S. shareholders of controlled foreign corporations to include in income a proportionate share of the CFC's "tested income" in excess of a deemed return on tangible assets. PBI, as a controlled foreign corporation wholly owned (through disregarded PHL) by PPC, is subject to the GILTI regime for TY 2018–2020.
To the extent that GILTI already captures a portion of PBI's income attributable to intangible property — which is precisely the type of income that GILTI was designed to reach — a § 367(d) adjustment would create a risk of triple-layer taxation: PPC would be taxed on (1) the § 367(d) deemed royalty, (2) the GILTI inclusion attributable to PBI's intangible income, and (3) any § 482 adjustments increasing PPC's income from cost-sharing payments and royalty rates. This triple-layer taxation risk is both economically unreasonable and inconsistent with the policy objectives of each individual provision.
The existence of GILTI significantly reduces the IRS's policy incentive to pursue § 367(d) recharacterization. One of the principal concerns that § 367(d) was designed to address — the shifting of intangible-related income to low-tax foreign affiliates — is now partially addressed by GILTI, which imposes a minimum tax on CFC intangible income regardless of whether the underlying IP was transferred in a nonrecognition transaction. To the extent that GILTI already subjects PBI's intangible income to U.S. taxation, a § 367(d) adjustment would provide diminishing marginal revenue to the IRS while creating significant complexity and double-taxation issues.
BEAT (IRC § 59A). The Base Erosion and Anti-Abuse Tax, enacted by the TCJA under IRC § 59A, imposes a minimum tax on certain "base erosion payments" made by applicable taxpayers to foreign related parties. If the IRS were to recharacterize the CSA under § 367(d), any resulting deemed royalty could paradoxically reduce PPC's BEAT exposure by treating a greater portion of income as U.S.-source income — effectively reducing the base erosion payments that are the predicate for BEAT liability. This counterintuitive result further illustrates the complexity that would arise from layering § 367(d) on top of the existing § 482 and TCJA frameworks.
In summary, the TCJA provisions make § 367(d) recharacterization less attractive to the IRS from a policy standpoint. GILTI already partially addresses the concern about intangible income shifting to low-tax foreign affiliates, and the interaction of § 367(d) with GILTI and BEAT would create significant complexity and potential for duplicative or even triple-layer taxation.
IX. Case Law and Precedent
A. Key Cases
While there is no single case directly addressing the application of § 367(d) to a properly structured QCSA with an arm's-length PCT payment, several significant Tax Court and appellate decisions inform the analysis of the boundary between § 367(d) and § 482 in the cost-sharing arrangement context.
Altera Corp. v. Commissioner. In Altera Corp. v. Commissioner, 145 T.C. 91 (2015), aff'd in part, rev'd in part, 941 F.3d 1200 (9th Cir. 2019), cert. denied, 141 S. Ct. 131 (2020), the central issue was whether Treasury Regulation § 1.482-7A(d)(2) — which required the inclusion of stock-based compensation in the cost pool of a CSA — was a valid exercise of the Treasury Department's regulatory authority. While the case did not directly address § 367(d), it is relevant to the present analysis in several respects. First, the litigation confirmed that § 482 is the governing provision for CSA pricing disputes; the IRS did not assert a § 367(d) theory in Altera, notwithstanding the significant value of the intangible property at issue. Second, the Ninth Circuit's analysis of the regulatory framework for CSAs reinforced the principle that the detailed rules of Treasury Regulation § 1.482-7 (and its predecessor, § 1.482-7A) provide the comprehensive mechanism for addressing transfer pricing issues in CSAs.
Harborview Corporation, Inc. v. Commissioner. In Harborview Corporation, Inc. v. Commissioner, 147 T.C. 68 (2016), vacated and remanded, 900 F.3d 610 (8th Cir. 2018), and its successor proceedings, the Tax Court examined the arm's-length royalty rate for intangible property licensed by a U.S. parent (Harborview Corporation) to its Puerto Rico subsidiary. The case is significant because it involved a substantial outbound license of valuable medical-device IP to a controlled foreign entity — precisely the type of arrangement that might invite a § 367(d) theory. Yet the IRS pursued the case exclusively under § 482, relying on the comparable uncontrolled transaction ("CUT") method and the arm's-length standard. The IRS's decision not to pursue § 367(d) in Harborview Corporation — despite the outbound licensing of highly valuable intangible property — is consistent with the IRS's general practice of relying on § 482 rather than § 367(d) in transfer pricing controversies involving ongoing intercompany arrangements.
Hollowell & Co. v. Commissioner. In Hollowell & Co. v. Commissioner, 148 T.C. 108 (2017), aff'd, 934 F.3d 976 (9th Cir. 2019), the Tax Court examined the PCT payment made by Amazon's Luxembourg subsidiary to Penmark Holdings in connection with a CSA covering the transfer of pre-existing intangible property. The case is directly relevant to the present analysis because it involved a CSA and PCT of substantial magnitude. The IRS challenged the PCT valuation under § 482 and did not assert a § 367(d) theory. The Tax Court's analysis confirmed that the § 482 framework — including the specified methods for valuing PCT payments under Treasury Regulation § 1.482-7(g) — is the appropriate mechanism for resolving PCT valuation disputes, and that the § 482 arm's-length standard governs the pricing of intangible property rights shared under a CSA.
The consistent thread running through Altera, Harborview Corporation, and Amazon is that the IRS has pursued § 482 — not § 367(d) — as its theory of adjustment in cases involving CSAs and outbound intangible property licenses. While these cases do not establish a formal "exclusive remedy" doctrine, they reflect a strong pattern of IRS practice that militates against the likelihood of a § 367(d) theory bein